CAM2602
Based on 1 publication(s) in Google Scholar
CAM2602 is an orally active Aurora A-TPX2 protein−protein interaction inhibitor with a human Kd of 19 nM for Aurora A. CAM2602 increases the proportion of PH3 positive cells while reducing P-T288 Aurora A levels. CAM2602 arrests tumor xenograft growth in mice. CAM2602 can be used for the research of cancer, such as acute T cell leukemia.
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 3056388-47-4
- Formula: C23H21ClN4O4S
- Molecular Weight:484.96
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Kinase Inhibitor Library
HY-L009
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Anti-Blood Cancer Compound Library
HY-L079
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) CAM2602
MoreAll Aurora Kinase Isoforms
More
Biological Activity
|
Aurora A 19 nM (Kd) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | GI50 |
21.8 μM
Compound: CAM2602
|
Growth inhibition of human HeLa cells incubated for 72 hrs by sulforhodamine B assay
Growth inhibition of human HeLa cells incubated for 72 hrs by sulforhodamine B assay
|
[PMID: 39190548] |
| Jurkat | GI50 |
10.3 μM
Compound: CAM2602
|
Growth inhibition of human Jurkat cells incubated for 72 hrs by CellTiter-Blue assay
Growth inhibition of human Jurkat cells incubated for 72 hrs by CellTiter-Blue assay
|
[PMID: 39190548] |
CAM2602 binds to purified human Aurora A kinase domain with a Kd of 19 nM, inhibiting the Aurora A-TPX2 protein-protein interaction[1].
CAM2602 (0.1-100 μM; 2 h) induces mislocalization of Aurora A from the mitotic spindle in mitotic HeLa cells with an EC50 of 6.1 μM[1].
CAM2602 (0.1-100 μM; 2 h) induces dephosphorylation of Aurora A at Thr288 in mitotic HeLa cells with an EC50 of 3.9 μM[1].
CAM2602 (1-1000 μM; 72 h) inhibits the viability of Jurkat acute T cell leukemia cells with a GI50 of 10.3 μM[1].
CAM2602 (1-1000 μM; 72 h) inhibits the viability of HeLa cervical adenocarcinoma cells with a GI50 of 21.8 μM[1].
CAM2602 (20 μM; 8 h) induces Aurora A inhibition in Jurkat acute T cell leukemia cells, marked by increased PH3-positive mitotic cells and reduced P-T288 Aurora A levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Jurkat acute T cell leukemia cells；HeLa cervical adenocarcinoma cells
-
Concentration:1-1000 μM
-
Incubation Time:72 h
-
Result:Reduced Jurkat cell viability in a dose-dependent manner, with a half-maximal growth inhibition concentration (GI50) of 10.3 μM.
Reduced HeLa cell viability in a dose-dependent manner, with a GI50 of 21.8 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-SCID gamma (NSG) mice (female, 5−7 weeks old for biomarker study; female, 6−8 weeks old for efficacy study)[1]
-
Dosage:200 mg/kg (biomarker study); 100 mg/kg (efficacy study); 150 mg/kg (efficacy study)
-
Administration:p.o.; single dose (biomarker study); daily; 26 days (efficacy study)
-
Result:Showed fold-increases in phosphorylated histone H3 (PH3) over vehicle controls at 8 and 12 h post single 200 mg/kg dose.
Decreased levels of Aurora A phosphorylated at Thr288 (P-Thr288) at 8 and 12 h post single 200 mg/kg dose.
Reached plasma concentrations of 350 μM at 8 h and 150 μM at 12 h post single 200 mg/kg dose.
Reached tumor concentrations of 70 μM at 8 h and 54 μM at 12 h post single 200 mg/kg dose.
Suppressed tumor growth relative to vehicle-treated mice with daily dosing of 100 mg/kg or 150 mg/kg for 26 days, with 150 mg/kg showing greater efficacy.
Caused no overt toxicity or body weight loss in treated mice.
Chemical Information
-
CAS No. 3056388-47-4
-
Appearance Solid
-
Molecular Weight 484.96
-
Formula C23H21ClN4O4S
-
Color White to off-white
-
SMILES
O=C(C1=CC(C2=CC=C(C(OC3=CC=CC=N3)=C2)Cl)=C4C(NC=C4)=C1C)NS(=O)(N(C)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Biol Chem
CEP55 promotes prostate cancer progression via TPX2-dependent activation of AURKA-PI3K-AKT signaling and inhibition of ferroptosis. [Abstract]2026 Mar;302(3):111218. PMID: 41617029
Solvent & Solubility
DMSO : 200 mg/mL (412.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (10.31 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0620 mL | 10.3101 mL | 20.6203 mL | 51.5506 mL |
| 5 mM | 0.4124 mL | 2.0620 mL | 4.1241 mL | 10.3101 mL | |
| 10 mM | 0.2062 mL | 1.0310 mL | 2.0620 mL | 5.1551 mL | |
| 15 mM | 0.1375 mL | 0.6873 mL | 1.3747 mL | 3.4367 mL | |
| 20 mM | 0.1031 mL | 0.5155 mL | 1.0310 mL | 2.5775 mL | |
| 25 mM | 0.0825 mL | 0.4124 mL | 0.8248 mL | 2.0620 mL | |
| 30 mM | 0.0687 mL | 0.3437 mL | 0.6873 mL | 1.7184 mL | |
| 40 mM | 0.0516 mL | 0.2578 mL | 0.5155 mL | 1.2888 mL | |
| 50 mM | 0.0412 mL | 0.2062 mL | 0.4124 mL | 1.0310 mL | |
| 60 mM | 0.0344 mL | 0.1718 mL | 0.3437 mL | 0.8592 mL | |
| 80 mM | 0.0258 mL | 0.1289 mL | 0.2578 mL | 0.6444 mL | |
| 100 mM | 0.0206 mL | 0.1031 mL | 0.2062 mL | 0.5155 mL |
Powered by Bioz